AbbVie (ABBV) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $2.5 billion.
- AbbVie's Non-Current Deferred Tax Liability fell 978.54% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 978.54%. This contributed to the annual value of $2.6 billion for FY2024, which is 286.25% down from last year.
- AbbVie's Non-Current Deferred Tax Liability amounted to $2.5 billion in Q3 2025, which was down 978.54% from $2.6 billion recorded in Q2 2025.
- AbbVie's 5-year Non-Current Deferred Tax Liability high stood at $5.9 billion for Q4 2021, and its period low was $2.0 billion during Q3 2022.
- Over the past 5 years, AbbVie's median Non-Current Deferred Tax Liability value was $2.7 billion (recorded in 2023), while the average stood at $2.9 billion.
- In the last 5 years, AbbVie's Non-Current Deferred Tax Liability soared by 29290.93% in 2021 and then tumbled by 4525.26% in 2022.
- Over the past 5 years, AbbVie's Non-Current Deferred Tax Liability (Quarter) stood at $5.9 billion in 2021, then fell by 20.61% to $4.7 billion in 2022, then crashed by 43.53% to $2.7 billion in 2023, then decreased by 2.86% to $2.6 billion in 2024, then decreased by 3.84% to $2.5 billion in 2025.
- Its Non-Current Deferred Tax Liability stands at $2.5 billion for Q3 2025, versus $2.6 billion for Q2 2025 and $2.6 billion for Q1 2025.